van der Zwan JM, Trama A, Otter R, Larrañaga N, Tavilla A, Marcos-Gragera R, et al. Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project. Eur J Cancer. 2013;49(11):2565–78.

Article  PubMed  Google Scholar 

Vahidfar N, Farzanehfar S, Abbasi M, Mirzaei S, Delpassand ES, Abbaspour F et al. Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [64Cu]Cu-DOTA-TOC. Cancers (Basel). 2022;14(1914).

Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology. 2004;80(Suppl 1):51–6.

Article  CAS  PubMed  Google Scholar 

Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: Biological, chemical and therapeutic aspects. Nature Reviews Drug Discovery. Volume 2. European Association for Cardio-Thoracic Surgery; 2003. pp. 999–1017.

Krenning EP, Breeman WAP, Kooij PPM, Lameris JS, Bakker WH, Koper JW, et al. Localisation of endocrine-related Tumours with Radioiodinated Analogue of somatostatin. Lancet. 1989;333:242–4.

Article  Google Scholar 

Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lawington V. ENETS Consensus guidelines for the standards of Care in neuroendocrine tumors: somatostatin receptor imaging with 111In-Pentetreotide. Neuroendocrinology. 2009;(90):184–9.

Krenning EP, Bakker WH, Kooij PPM, Breeman WA. P. somatostatin receptor scintigraphy with Indium 111-DTPA-D-Phe-1-Octreotide in Man: metabolism, Dosimetry and comparison with Iodine- 123-Tyr-3-Octreotide. J Nuclear Med. 1992;33(5):652–8.

CAS  Google Scholar 

Van Binnebeek S, Vanbilloen B, Baete K, Terwinghe C, Koole M, Mottaghy FM, et al. Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: a lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours. Eur Radiol. 2016;26(3):900–9.

Article  PubMed  Google Scholar 

Lee I, Paeng JC, Lee SJ, Shin CS, Jang JY, Cheon GJ, et al. Comparison of diagnostic sensitivity and quantitative indices between 68Ga-DOTATOC PET/CT and 111In-Pentetreotide SPECT/CT in neuroendocrine tumors: a preliminary Report. Nucl Med Mol Imaging. 2015;49(4):284–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, et al. Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol. 2016;34(6):588–97.

Article  CAS  PubMed  Google Scholar 

Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, et al. ENETS Consensus guidelines for the standards of Care in Neuroendocrine tumors: Radiological, Nuclear Medicine and Hybrid Imaging. Neuroendocrinology. 2017;105(3):212–44.

Article  CAS  PubMed  Google Scholar 

Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS Consensus guidelines for the standards of Care in Neuroendocrine neoplasms: peptide receptor Radionuclide Therapy with Radiolabelled somatostatin analogues. Neuroendocrinology. 2017;105(3):295–309.

Article  CAS  PubMed  Google Scholar 

Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA- conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37(10):2004–10.

Article  PubMed  Google Scholar 

Anderson CJ, Pajeau TS, Edwards WB, Sherman ELC, Rogers BE, Welch MJ. In Vitro and in vivo evaluation of copper-64-Octreotide conjugates. J Nuclear Med. 1995;36(12):2315–25.

CAS  Google Scholar 

Pfeifer A, Knigge U, Binderup T, Mortensen J, Oturai P, Loft A, et al. 64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-Head comparison with 111In-DTPA-Octreotide in 112 patients. J Nucl Med. 2015;56(6):847–54.

Article  CAS  PubMed  Google Scholar 

Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, et al. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med. 2012;53:1207–15.

Article  CAS  PubMed  Google Scholar 

Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, et al. Head-to-Head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors. J Nucl Med. 2017;58:451–7.

Article  CAS  PubMed  Google Scholar 

Loft M, Carlsen EA, Johnbeck CB, Johannesen HH, Binderup T, Pfeifer A, et al. 64Cu-DOTATATE PET in patients with neuroendocrine neoplasms: prospective, head-to-head comparison of imaging at 1 hour and 3 hours after injection. J Nucl Med. 2020;62(1):62–8.

Google Scholar 

Carlsen EA, Johnbeck CB, Binderup T, Loft M, Pfeifer A, Mortensen J, et al. 64Cu-DOTATATE PET/CT and prediction of overall and progression-free survival in patients with neuroendocrine neoplasms. J Nucl Med. 2020;61(10):1491–7.

Article  CAS  PubMed  Google Scholar 

Delpassand ES, Ranganathan D, Wagh N, Shafie A, Gaber A, Abbasi A, et al. 64Cu-DOTATATE PET/CT for imaging patients with known or suspected somatostatin receptor-positive neuroendocrine tumors: results of the first U.S. prospective, reader-masked clinical trial. J Nucl Med. 2020;61(6):890–6.

Article  CAS  PubMed  Google Scholar 

Fani M, Nicolas GP. 61Cu-Labeled Radiotracers: Alternative or Choice? Journal of Nuclear Medicine [Internet]. 2023;64(12):1855–7. Available from: http://jnm.snmjournals.org/lookup/doi/https://doi.org/10.2967/jnumed.123.266171

Fonseca AI, Alves VH, do Carmo SJC, Silva M, Hrynchak I, Alves F et al. Production of GMP-Compliant Clinical amounts of Copper-61 radiopharmaceuticals from Liquid targets. Pharmaceuticals. 2022;15(6).

Jacobs S, Schulz S. Intracellular trafficking of somatostatin receptors. Mol Cell Endocrinol. 2008;286(1–2):58–62.

Article  CAS  PubMed  Google Scholar 

Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of Radiolabeled somatostatin analogs for Cancer Imaging and Therapy. Molecules. 2020;25(17).

Dewulf J, Flieswasser T, Delahaye T, Vangestel C, Miranda A, de Haard H et al. Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models. EJNMMI Radiopharm Chem. 2023;8(1).

Robu S, Richter A, Gosmann D, Seidl C, Leung D, Hayes W, et al. Synthesis and preclinical evaluation of a 68Ga-Labeled adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 expression. J Nucl Med. 2021;62(9):1228–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Houson HA, Tekin V, Lin W, Aluicio-Sarduy E, Engle JW, Lapi SE. PET imaging of the neurotensin targeting peptide NOTA-NT-20.3 using Cobalt-55, Copper-64 and Gallium-68. Pharmaceutics. 2022;14(12).

Domnanich KA, Müller C, Farkas R, Schmid RM, Ponsard B, Schibli R et al. 44Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations. EJNMMI Radiopharm Chem [Internet]. 2016;1(81):1–19. Available from: https://doi.org/10.1186/s41181-016-0013-5

Xia Y, Zeng C, Zhao Y, Zhang X, Li Z, Chen Y. Comparative evaluation of 68Ga-labelled TATEs: the impact of chelators on imaging. EJNMMI Res. 2020;10(1).

Pfeifer A, Johnbeck CB, Knigge U, Mortensen J, Oturai P, Loft A et al. Clinical PET imaging of neuroendocrine tumors using 64Cu-DOTA-Tyr3-octreotate. Journal of Nuclear Medicine [Internet]. 2013;54(supplement 2):1854. Available from: https://jnm.snmjournals.org/content/54/supplement_2/1854

Jiang Y, Liu Q, Wang G, Sui H, Wang R, Wang J, et al. Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors. Theranostics. 2022;12(15):6437–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Clement D, Navalkissoor S, Srirajaskanthan R, Courbon F, Dierickx L, Eccles A, et al. Efficacy and safety of 177LuDOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study. Eur J Nucl Med Mol Imaging. 2022;49(10):3529–37.

Article  CAS  PubMed  Google Scholar 

Yadav MP, Ballal S, Bal C, Sahoo RK, Damle NA, Tripathi M et al. Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients. Clin Nucl Med [Internet]. 2020;45(1):19–31. Available from: https://journals.lww.com/nuclearmed/fulltext/2020/01000/efficacy_and_safety_of_177lu_psma_617_radioligand.4.aspx

Demirkol MO, Esen B, Seymen H, Şen M, Uçar B, Kurtuldu S et al. Radioligand Therapy With 177Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer: Oncological Outcomes and Toxicity Profile. Clin Nucl Med [Internet]. 2023;48(12). Available from: https://journals.lww.com/nuclearmed/fulltext/2023/12000/radioligand_therapy_with_177lu_psma_i_t_in.40.aspx

Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S, et al. microPET Imaging of Glioma Integrin αvβ3 expression using 64Cu-Labeled tetrameric RGD peptide. J Nuclear Med. 2005;46(10):1707–18.

CAS  Google Scholar 

McQuade P, Miao Y, Yoo J, Quinn TP, Welch MJ, Lewis JS. Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH. J Med Chem. 2005;48(8):2985–92.

Article  CAS  PubMed  Google Scholar 

Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, Jurisson SS, et al. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med. 2007;48(8):1327–37.

Article  CAS  PubMed  Google Scholar 

Boswell CA, Sun X, Niu W, Weisman GR, Wong EH, Rheingold AL, et al. Comparative in vivo Stability of Copper-64-Labeled Cross-bridged and Conventional Tetraazamacrocyclic complexes. J Nucl Med. 2004;47:1465–74.

CAS  Google Scholar 

Hanaoka H, Tominaga H, Yamada K, Paudyal P, Iida Y, Watanabe S, et al. Evaluation of 64Cu-labeled DOTA-d-Phe1-Tyr 3-octreotide (64Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors. Ann Nucl Med. 2009;23(6):559–67.

Article  CAS  PubMed  Google Scholar 

Lewis JS, Laforest R, Lewis M, Anderson CJ. Comparative dosimetry of Copper-64 and Yttrium-90-Labeled somatostatin analogs in a tumor-bearing rat model. Cancer Biotherapy Radiopharmaceuticals. 2000;15(6):593–604.

Article  CAS  PubMed  Google Scholar 

Paterson BM, Roselt P, Denoyer D, Cullinane C, Binns D, Noonan W, et al. PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate. Dalton Trans. 2014;43(3):1386–96.

Article  CAS  PubMed